|
Terry Rugg, M.D., joined us in August 2006 as Chief Medical Officer (CMO) and Vice President of Development. Terry is an Oncologist with 16 years of cancer specific industry experience; having occupied international and US focused positions in both large and small pharmaceutical companies, including Eli Lilly and Company, Zeneca Pharmaceuticals, Ilex Oncology and British Biotech. Terry commenced his career with Eli Lilly, and played a key role in the successful development of Gemzar® (gemcitabine) for small cell lung cancer and pancreatic cancer. Beyond gemcitabine, Terry has been intimately involved in the development and successful registration of both Campath® (CD52 targeted monoclonal antibody indicated for CLL) and Clolar® (clofarabine), indicated in pediatric leukemias. Terry also has extensive FDA (IND, NDA and BLA), EMEA (CTX, DDX and MAA) and other regulatory experience, and most recently, Medical Affairs experience. Terry joins us from Sanofi-Aventis, where he held the Vice President position of Head of Oncology, Global Medical Affairs (Aventis) and more recently, Head of Oncology, US Medical Affairs (Sanofi-Aventis) where he led a department of approximately 59 Regional and National Liaisons and MDs. Terry received his M.D. from the University of Rhodesia, Godfrey Higgins School of Medicine and Surgery. | 